Connection

J. THORNTON to Narcotic Antagonists

This is a "connection" page, showing publications J. THORNTON has written about Narcotic Antagonists.
Connection Strength

2.472
  1. Concurrent Depression Management in Patients with Opioid Use Disorder Undergoing Buprenorphine Therapy: Association with Buprenorphine Discontinuation. J Dual Diagn. 2025 Apr; 21(2):142-151.
    View in: PubMed
    Score: 0.899
  2. Impact of COVID-19 Related Policy Changes on Buprenorphine Dispensing in Texas. J Addict Med. 2020 12; 14(6):e372-e374.
    View in: PubMed
    Score: 0.666
  3. Understanding the financial barriers to treatment among individuals with opioid use disorder: a focus group study. Harm Reduct J. 2024 Dec 20; 21(1):220.
    View in: PubMed
    Score: 0.220
  4. Patients' willingness to pay for naloxone: A national cross-sectional survey of prescription opioid users with chronic pain in the United States. J Am Pharm Assoc (2003). 2024 May-Jun; 64(3):102062.
    View in: PubMed
    Score: 0.208
  5. Intention to get naloxone among?patients prescribed opioids for chronic pain. Harm Reduct J. 2022 Sep 22; 19(1):104.
    View in: PubMed
    Score: 0.189
  6. Applying the capability, opportunity, motivation, and behavior model to identify opportunities to increase pharmacist comfort dispensing naloxone in Texas: A structural equation modeling approach. Int J Drug Policy. 2020 09; 83:102827.
    View in: PubMed
    Score: 0.162
  7. Pharmacists' readiness to provide naloxone in community pharmacies in West Virginia. J Am Pharm Assoc (2003). 2017 Mar - Apr; 57(2S):S12-S18.e4.
    View in: PubMed
    Score: 0.128
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.